Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Besides which, I topped up my shareholding earlier today although it is not yet shown.
Adastra: I view with suspicion talk of a takeover of IMM by a larger pharma company. Having followed IMM through thick and thin for a decade, I do not think IMM should duck out at this stage or any other stage. If it is on the "Cusp" of great developments as predicted by Tim McC, what a stupid time this would be to sell out. We are told that a deal to finance the Phase 2/3 Trial of CIDP is close, and further news is expected very soon for details of the Lupuzor Phase 3 Trial, AND we are due to receive dividends on IMM's shares in Incanthera by H2 of this year. In these circumstances, why sell IMM to a big fish when the price is at an alltime low?
Adastra:
"The CIDP programme is gaining a lot of interest from Pharma companies".
Haven't we heard that many months ago from Tim? But there has not been a cheep from him about this "interest" since then.
Pokerchips:
You are mistaken in seeming to state that there will not be dividends for shareholders in INC. Tim, in his Proactive interview, made it very clear that dividends will be paid to shareholders if his predicted revenues come true in the second half of 2024. To listen to him, it is going to JIngle, Jingle at the INC cash till from 2024 onwards and a very lucrative time for its shareholders.
Adastra: Thanks for providing today's and yesterday's posts which contain a good summary of the case for investing in IMM, particularly when the SP is at this extrem low point. I hope that it comes true in the next few months.
Flash: I recall that you wrote that you had sold all your IMM shares, you were so disgusted with the company. Why are you still around, spreading your scare stories as in the past?
Wild tiger:
Lucky you selling at 1.85p recently. I can't see any buy above 1.75p during the recent price spike.
With this latest notification of a disposal of over 8 million shares, Lanstead has reduced its holding by 24 million in December. Despite this, the price has strengthened. Interesting and probably encouraging. What would the price have been if Lanstead had not been off-loading? At this rate Lanstead will have disposed of its entire 16% holding by mid-March, not that I expect them to do so.
The most recent RNS of 19th December reveals that Lanstead reduced its shareholding by approx 4%. From the percentage difference of their holding one can calculate that the disposed of 16.4 million shares. Does that mean that they have been acquired by private shareholders like us? If so, I find it comforting that despite this, the SP has remained solid at arount 1.6 p. I guess that there is a lot of positive sentiment about IMM tho' not enough yet to left the price substantially.
And Lords of lolly, thanks for your very revealing post about Flash's post from Dec 2022.What a chancer!
Flash.
Since you have sold your millions of shares at a loss of only 10%,congratulations. Now just scarper, scram, BO.
You have sung your song and it's getting decidedly scratchy.
Then let us all remember you as Flash-in-the-Pan.
Bravo Dallo!
You confirm my view: why the Doom and Gloom?
The messages from Flash and others predicting doom and gloom for IMM seem very far fetched.
After all the clamour to be given news about a new Phase 3 trial for Lupuzor, we have it: Simbec-Orion has been selected to be the CRO and has started on the road to selecting patients; animal testing with high doses of Lupuzor has shown it to be tolerated at much higher dose levels than were used in the first Phase 3 trial; and Avion is still onboard with the budget for carrying out the new trial.
So we don't know when the dosing of patients will start. Of course there will be a wait before we are given this date, but let's get our language right; this is a wait, not a delay. But I hope that we will be given a first dosing date towards the end of H1, 2024, as Nolupus has said.
I also think that it is possible that a deal will be done by H1, 2024, for ROW rights to Lupuzor and/or to finance a Phase 2/3 Trial on P140 for CIDP.
So it seems to me to be premature to sell now. Admittedly, since you seem to have bought at mainly sub-1.7p you may not be sitting on such large losses as us who bought over many years at much higher prices than you.
Flash:
I believe that you are wrong in stating the Lupuzor Trial has been postponed. It has been started with the appointment of Simbec-Orion as CRO. As I've already, the trial is live, it is on-going and the CRO is liasing with clinicians to identify and recruit patients for the Trial. I presume that this takes several weeks because several countries and many testing centres will be included.
Only when this has been done will the Trial begin in the sense of administering the Lupuzor drug or the placebo, to the selected patients. But all the active preparatory work is going on right now. If you doubt this, why don't you phone Lisa Baderoon or Tim McCarthy yourself?
It is amazing how negative the comments are about this RNS.
It is surely very good news that a CRO has been appointed and that Avion are on board. The trial is live and work is on-going on the selection process of patients who will be taking part in the trial. It is clear that behind-the-scenes work has been taking place on animal trials using much higher levels of Lupuzor which will now inform the new Phase 3 Lupuzor trial. It is a misunderstanding on the part of many commentators that Simbec-Orion are sitting on their hands. They are not, they have been given the go-ahead to go ahead with the Trial. No doubt it will take some weeks to choose the patients for the Trial in the countries where it is being conducted, and when the first of them will be treated with Lupuzor.
Other prep. work is surely being undertaken, for example to ensure that sufficient amounts of Lupuzor have been manufactured for the trial.
I therefore feel confident that by this time in 2024 we shall be in a much better place with regard to Lupuzor.
Wildbunch:
Thanks for your insightful comments about the near to mid-term future of Imm, Lupuzor and P140 treatment of CIDP, etc. Also your comments about Dr Reilly's appointment to the Board; he certainly seems to have the appropriate experience and skills to help IMM to establish partnerships with other pharma companies to finance trials and to commercialise Imm's future drug candidates.
I'm waiting with bated breath to see what next week brings by way of an important RNS from IMM.
Dallo:
Thanks for that. But remember Tim is only the mouthpiece. It's the pharma experts behind the scenes, especially the ones who represent Avion, who will write his script and decide when it is appropriate to pronounce it.
Flash/Dallo.
Thanks for your insights into the rapid oscillations in the IMM share price. I am still averaging down from the earlier heights I bought IMM shares 5 and more years ago. I don't mind who the sellers are who make this possible.
But surely there will come a time, perhaps after the next RNS, when it will pay Lanstead to let the upward pressure out of the bottle and let the price rip up. They have a huge shareholding in IMM and it is surely the case that the gain they will make from the share appreciation will far outweigh the benefit they obtain from suppressing the SP and having to pay out lower instalments on their loan agreement with IMM. I think this is only a matter of time - perhaps a very short time.
LLofL.
There is no sign that Avion has chucked in the towel; why would they? So I think that the SP is highly unlikely to trade below 1p.
MavD:
I agree; an RNS either this week of next. Avion and IMM will be doing their utmost to issue one before Christmas.
And I have a feeling that by the end of this year we will say goodbye to trading below 2p. I'm very glad that I concluded buys at below 2p during the past few weeks. A bargain price which I believe will not be repeated beyond this month.
Nolupus:
Shares in issue - good point. But 25 times as many now compared with then? Where do I go to find out?